TME Pharma N.V.
ALTME | Euronext Growth
Overview
Corporate Details
- ISIN(s):
- NL0015000YE1 (+1 more)
- LEI:
- 724500EPNADXWZ58U595
- Country:
- Germany
- Address:
- Max-Dohrn-Strasse 8-10, 10589 Berlijn
- Website:
- https://www.tmepharma.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma�s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Our clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned.�
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for TME Pharma N.V..
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-18 08:00 |
Regulatory News Service
Inside Information / Other news releases
|
English | 255.7 KB | |
| 2025-06-18 08:00 |
M&A Activity
Informations privilégiées / Autres communiqués
|
French | 287.8 KB | |
| 2025-05-27 08:00 |
Capital/Financing Update
Inside Information / Other news releases
|
English | 386.1 KB | |
| 2025-05-27 08:00 |
Capital/Financing Update
Informations privilégiées / Autres communiqués
|
French | 388.7 KB | |
| 2025-05-26 08:00 |
Pre-Annual General Meeting Information
Informations privilégiées / Autres communiqués
|
French | 261.4 KB | |
| 2025-05-26 08:00 |
Pre-Annual General Meeting Information
Inside Information / Other news releases
|
English | 222.6 KB | |
| 2025-05-21 08:00 |
Capital/Financing Update
Informations privilégiées / Autres communiqués
|
French | 329.1 KB | |
| 2025-05-21 08:00 |
Capital/Financing Update
Inside Information / Other news releases
|
English | 286.1 KB | |
| 2025-05-05 18:00 |
Director's Dealing
Inside Information / Other news releases
|
English | 243.3 KB | |
| 2025-05-05 18:00 |
Director's Dealing
Informations privilégiées / Autres communiqués
|
French | 255.1 KB | |
| 2025-05-05 08:00 |
Board/Management Information
Inside Information / Other news releases
|
English | 281.1 KB | |
| 2025-05-05 08:00 |
Board/Management Information
Informations privilégiées / Autres communiqués
|
French | 287.8 KB | |
| 2025-04-25 18:00 |
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
|
French | 351.1 KB | |
| 2025-04-25 18:00 |
Earnings Release
Inside Information / News release on accounts, results
|
English | 275.9 KB | |
| 2025-04-10 19:00 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 224.0 KB |
Automate Your Workflow. Get a real-time feed of all TME Pharma N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for TME Pharma N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
BioPorto | Denmark | BIOPOR | |
|
BioSenic SA | Belgium | BIOS | |
|
Biosergen AB | Sweden | BIOSGN | |
|
BIOTECH | Spain | BST | |
|
Biotest AG | Germany | BIO3 | |
|
Bioton S.A. | Poland | BIO | |
|
Bioversys N | Switzerland | BIOV | |
|
Biovica International B | Sweden | BIOVIC | |
|
Bonus BioGroup Ltd. | Israel | BONS | |
|
BRAIN Biotech AG | Germany | BNN |